Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome.

Roufosse, Florence; Butterfield, Joseph; Steinfeld, Jonathan; Bentley, Jane H; von Maltzahn, Robyn; Kwon, Namhee; Nelsen, Linda

Roufosse, Florence; Butterfield, Joseph; Steinfeld, Jonathan; Bentley, Jane H; von Maltzahn, Robyn; Kwon, Namhee; Nelsen, Linda.

Afiliação

Roufosse F; Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Butterfield J; Division of Allergic Diseases and the Mayo Clinic Program for Mast Cell and Eosinophil Disorders, Mayo Clinic, Rochester, MN, United States.
Steinfeld J; Respiratory Research & Development, GSK, Collegeville, PA, United States.
Bentley JH; Value Evidence and Outcomes, GSK, GSK House, Brentford, Middlesex, United Kingdom.
von Maltzahn R; Value Evidence and Outcomes, GSK, GSK House, Brentford, Middlesex, United Kingdom.
Kwon N; Respiratory Research & Development, GSK, GSK House, Brentford, Middlesex, United Kingdom.
Nelsen L; Value Evidence and Outcomes, GSK, Collegeville, PA, United States.

Front Med (Lausanne) ; 10: 1035250, 2023.

Article em En | MEDLINE | ID: mdl-37064032

Palavras-chave

HES-DS; daily symptoms; hypereosinophilic syndrome (HES); mepolizumab; most bothersome; patient-reported

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google